552 completed, 52 recruiting, 51 terminated, 45 unknown. 758 Phase 1, 130 Phase 2.
Follow Renal Insufficiency: new trials by email Literature Review of Renal Insufficiency trials Research Report on Renal Insufficiency
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-Interleukin-6 (IL6) in Calciphylaxis Tocilizumab - Calciphylaxis | Phase 1 | Not yet recruiting | Boston Medical Center | 10 | 2027-09-01 | 2026-07-16 |
| Breakthrough - T1DM and Chronic Kidney Disease Tegoprubart, Islet Cell Transplant - Diabete Type 1, Chronic Kidney Disease | Phase 1 / Phase 2 | Recruiting | University of Chicago | 10 | 2027-04-29 | 2026-08-20 |
| Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis Bupropion Hydrochloride 150 MG - End Stage Renal Disease, Fatigue | Phase 1 / Phase 2 | Not yet recruiting | The University of Texas Health Science Center at San Antonio | 16 | 2027-02-01 | 2026-11-02 |
| A Clinical Trial of MK-6916 in Participants With Moderate and Severe Kidney Disease Compared to Healthy Controls (MK-6916-013) MK-6916 - Healthy, Renal Impairment | Phase 1 | Not yet recruiting | Merck Sharp & Dohme LLC | 32 | 2026-12-11 | 2026-11-06 |
| A Study to Learn About the Study Medicine Called Prifetrastat in People With Renal Impairment Prifetrastat - Renal Impairment, Healthy Adults | Phase 1 | Not yet recruiting | Pfizer | 24 | 2026-11-17 | 2026-11-12 |
| Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD GGTA1 KO Thymokidney - ESRD (End-Stage Renal Disease), Kidney Transplantation | Phase 1 / Phase 2 | Recruiting | United Therapeutics | 50 | 2026-11-01 | 2026-09-09 |
| A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment Revumenib - Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia | Phase 1 | Not yet recruiting | Syndax Pharmaceuticals | 18 | 2026-11-01 | 2026-11-06 |
| Study of CTX001 in Adults With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease Placebo, CTX001, Ferrous Sulfate - Chronic Kidney Disease, Anemia | Phase 1 | Not yet recruiting | Cajal Therapeutics Inc. | 24 | 2026-11-01 | 2026-10-28 |
| A Study of Tersolisib (LY4064809) in Participants With Kidney Impairment Compared With Participants With Normal Kidney Function Tersolisib - Renal Insufficiency, Healthy Participant | Phase 1 | Not yet recruiting | Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company | 32 | 2026-11-01 | 2026-11-09 |
| Study of ChoironeX GalKO Porcine Thymokidney Xenotransplantation in End-Stage Renal Disease ChoironeX GalKO Porcine Thymokidney - End Stage Renal Disease | Phase 1 | Recruiting | Xeno Holdings (US), LLC dba ChoironeX | 4 | 2026-11-01 | 2026-11-10 |
| A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Impaired Renal Function and Participants on Hemodialysis INCB161734 - Renal Insufficiency, Kidney Diseases | Phase 1 | Not yet recruiting | Incyte Corporation | 24 | 2026-10-26 | 2026-10-02 |
| A Study to Investigate the Effects of Moderate or Severe Renal Impairment (RI) on Velzatinib Velzatinib - Healthy Participants, Gastrointestinal Neoplasms | Phase 1 | Not yet recruiting | GlaxoSmithKline | 30 | 2026-10-23 | 2026-10-09 |
| A Study to Investigate the Pharmacokinetics and Safety of PKN605 in Participants With Moderate and Severe Renal Impairment Compared to Matched Control Subjects With Normal Renal Function PKN605 - Participants With Moderate and Severe Renal Impairment and Healthy Participants | Phase 1 | Recruiting | Novartis Pharmaceuticals | 40 | 2026-10-01 | 2026-11-06 |
| Study of Sulthiame (S-054502) in Participants With Renal Impairment and Matched Healthy Controls Sulthiame - Renal Impairment | Phase 1 | Not yet recruiting | Shionogi | 30 | 2026-09-29 | 2026-10-05 |
| Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Participants With Severe Renal Impairment Compared to Matched Participants With Normal Renal Function rilzabrutinib - Renal Impairment, Healthy Volunteers | Phase 1 | Recruiting | Sanofi | 16 | 2026-09-22 | 2026-10-23 |
| Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis REGN9933, REGN7508, REGN9533 - End-Stage Kidney Disease (ESKD) | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 36 | 2026-09-17 | 2026-10-06 |
| Renal Impairment Pharmacokinetics (PK) Trial of Afabicin Afabicin Oral, Afabicin IV - Renal Impairment | Phase 1 | Recruiting | Debiopharm International SA | 60 | 2026-09-16 | 2026-10-26 |
| A Study Investigating the Safety of RO7795081 and How the Body Processes RO7795081 in People With Normal or Decreased Kidney Functions RO7795081 - Renal Impairment | Phase 1 | Recruiting | Hoffmann-La Roche | 60 | 2026-09-09 | 2026-11-09 |
| A Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027) Nemtabrutinib - Severe Renal Impairment, Healthy | Phase 1 | Recruiting | Merck Sharp & Dohme LLC | 20 | 2026-09-08 | 2026-09-23 |
| A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function Golcadomide - Kidney Failure, Chronic | Phase 1 | Recruiting | Bristol-Myers Squibb | 30 | 2026-09-08 | 2026-10-01 |
Showing 20 of 758. Sign in to see all of them.
Renal Insufficiency, Chronic (212) · Kidney Failure, Chronic (182) · Kidney Diseases (46) · Acute Kidney Injury (40) · Diabetes Mellitus, Type 2 (24) · Anemia (18) · Heart Failure (15) · Diabetes Mellitus (9) · Lymphoma, Follicular (9) · Diabetic Nephropathies (8) · Neoplasms (8) · Cardiovascular Diseases (7) · Multiple Myeloma (7) · Hyperparathyroidism, Secondary (6)
Female Urogenital Diseases (758) · Female Urogenital Diseases and Pregnancy Complications (758) · Male Urogenital Diseases (758) · Urogenital Diseases (757) · Urologic Diseases (752) · Kidney Diseases (712) · Pathological Conditions, Signs and Symptoms (393) · Pathologic Processes (389) · Disease Attributes (375) · Chronic Disease (370) · Renal Insufficiency, Chronic (151) · Nutritional and Metabolic Diseases (55) · Metabolic Diseases (51) · Cardiovascular Diseases (49)
Kidney Transplantation (9) · Sodium Chloride (9) · spleen fibrinolytic proteinase (human) (9) · Rituximab (8) · Saline Solution (8) · Tacrolimus (7) · ferric pyrophosphate (7) · Cyclophosphamide (6) · Dabigatran (5) · Mycophenolic Acid (5) · Tablets (5) · ZD4054 (5) · dapagliflozin (5) · roxadustat (5) · Epoetin Alfa (4)
AstraZeneca (37) · Merck Sharp & Dohme LLC (28) · Pfizer (25) · Novartis Pharmaceuticals (23) · Bayer (20) · Eli Lilly and Company (16) · Boehringer Ingelheim (13) · Amgen (12) · GlaxoSmithKline (12) · Mayo Clinic (10) · Janssen Research & Development, LLC (9) · Rockwell Medical Technologies, Inc. (9) · Bristol-Myers Squibb (8) · Massachusetts General Hospital (8) · Astellas Pharma Inc (6)
United States (414) · Germany (84) · China (51) · United Kingdom (21) · Canada (18) · South Korea (16) · Japan (15) · Australia (14) · Bulgaria (14) · Czechia (13) · France (13) · Hungary (12) · Romania (12) · Belgium (11) · New Zealand (9)
PMID 32446407, PMID 30677788, PMID 40576086, PMID 24030917, PMID 33115916, PMID 36005278, PMID 37916745, PMID 38770818, PMID 38995690, PMID 40009460, PMID 40333016, PMID 11705426, PMID 15269196, PMID 17468348, PMID 17551901, PMID 17634080, PMID 17660031, PMID 17999333, PMID 18216355, PMID 18385391, PMID 18513531, PMID 18633105, PMID 18643743, PMID 19376616, PMID 19479191, PMID 19692415, PMID 19776051, PMID 19822798, PMID 20876669, PMID 21176752, PMID 21354682, PMID 21714604, PMID 21726829, PMID 21952084, PMID 21960668, PMID 22008366, PMID 22173804, PMID 22457244, PMID 22657252, PMID 22970753, PMID 23036928, PMID 23172172, PMID 23241359, PMID 23359360, PMID 23737404, PMID 23797006, PMID 23903014, PMID 24022265, PMID 24197066, PMID 24374856
2017 (8), 2019 (8), 2014 (7), 2018 (6), 2016 (5), 2015 (3), 2023 (3), 2008 (2), 2009 (2), 2025 (2), R01DK099199 (2), U01CA062490 (2), UM1CA186690 (2), UM1CA186691 (2), UM1CA186709 (2)